The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
2021
-
Comment Letter
Mycophenolate Mofetil for Immune Thrombocytopenia. Reply.
-
Randomized Controlled Trial Multicenter Study
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity in vitro against current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. ⋯ REGEN-COV reduced the risk of Covid-19-related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04425629.).